TRINETRA › Sectors › Healthcare
Senores Pharmaceuticals Limited (SENORES) — share price, P/E and fundamentals
Senores Pharmaceuticals Limited (NSE: SENORES) closed at ₹1,133.90 on 30 Oct 2026, +58.6% over one year, against a 52-week range of ₹706.00 – ₹1,599.00.
In the quarter ended 30 Sept 2026 (consolidated, filed 29 Oct 2026) it reported revenue of ₹192 cr and net profit of ₹39 cr, a 20.5% net margin; revenue grew 18.9% and profit grew 17.1% year on year.
On four consecutive filed quarters its trailing P/E is 51.3; since 19 May 2025 its own P/E has ranged from 31.1 to 56.1 (median 44.2), and today's reading is higher than 24% of those 359 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 15.8%, ROCE 17.8%, debt-to-equity 0.39, Piotroski F-score 5 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 76% of 63 sector peers; PBT margin higher than 73% of 63 sector peers; ROE higher than 60% of 63 sector peers.
Key figures
| Last close | ₹1,133.90 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -15.7% / +27.2% / +58.6% |
| 52-week low – high | ₹706.00 – ₹1,599.00 |
| Market capitalisation | ₹5,222 cr |
| Trailing P/E | 51.3 |
| Price / book | 5.21 |
| EV / EBITDA | 22.8 |
| Earnings yield | 2.0% |
| TTM EPS | ₹22.12 |
| TTM net profit | ₹102 cr |
| Quarter revenue | ₹192 cr |
| Quarter net profit | ₹39 cr |
| Net margin | 20.5% |
| Revenue growth (YoY) | +18.9% |
| Profit growth (YoY) | +17.1% |
| Return on equity | 15.8% |
| ROCE | 17.8% |
| Debt / equity | 0.39 |
| Current ratio | 1.86 |
| Free cash flow | ₹-107 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹27.1 cr |
Against Healthcare peers
| Metric | SENORES | Peer median | Percentile |
|---|---|---|---|
| Net margin | 20.53 | 12.67 | 76 |
| PBT margin | 24.74 | 17.57 | 73 |
| ROE | 15.75 | 13.86 | 60 |
| ROCE | 17.76 | 16.59 | 52 |
| Debt / equity | 0.39 | 0.11 | 78 |
| FCF margin | -28.82 | 2.08 | 0 |
| Cash conversion | 0.44 | 1.25 | 12 |
| Trailing P/E | 51.26 | 43.07 | 56 |
Questions
What is the P/E ratio of Senores Pharmaceuticals Limited?
Senores Pharmaceuticals Limited's trailing P/E is 51.3, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 19 May 2025 its P/E has ranged 31.1–56.1.
What were Senores Pharmaceuticals Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Senores Pharmaceuticals Limited reported revenue of ₹192 cr and net profit of ₹39 cr (consolidated), filed with the exchange on 29 Oct 2026.
What is Senores Pharmaceuticals Limited's ROE?
Return on equity is 15.8% based on the balance sheet dated 30 Sept 2026.
Does Senores Pharmaceuticals Limited have debt?
Debt-to-equity is 0.39 on the balance sheet dated 30 Sept 2026.
What is SENORES's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, SENORES traded between ₹706.00 and ₹1,599.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.